CU20200068A7 - Glicoconjugados de precisión como herramientas terapéuticas - Google Patents

Glicoconjugados de precisión como herramientas terapéuticas

Info

Publication number
CU20200068A7
CU20200068A7 CU2020000068A CU20200068A CU20200068A7 CU 20200068 A7 CU20200068 A7 CU 20200068A7 CU 2020000068 A CU2020000068 A CU 2020000068A CU 20200068 A CU20200068 A CU 20200068A CU 20200068 A7 CU20200068 A7 CU 20200068A7
Authority
CU
Cuba
Prior art keywords
glycoconjugates
precision
carrier proteins
immunogenic carrier
therapeutic tools
Prior art date
Application number
CU2020000068A
Other languages
English (en)
Inventor
René Roy
Tze Chieh Shiao
Original Assignee
Koranex Capital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koranex Capital filed Critical Koranex Capital
Publication of CU20200068A7 publication Critical patent/CU20200068A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001172—Sialyl-Thomson-nouvelle antigen [sTn]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/738—Cross-linked polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

<p>La presente descripción se refiere a glicoconjugados, inmunógenos de glicoconjugados y vacunas de glicoconjugados que comprenden antígenos de carbohidrato acoplados a proteínas portadoras inmunogénicas, o materiales utilizados para la detección y el cribado de anticuerpos resultantes. Se describen métodos mejorados para conjugar de manera más directa y precisa antígenos de carbohidrato con grupos tiol libres de proteínas portadoras inmunogénicas, incluidos los enfoques de ¨química clic¨ basados en reacciones de tiol-eno fotocatalíticas.</p>
CU2020000068A 2018-03-23 2019-03-22 Glicoconjugados de precisión como herramientas terapéuticas CU20200068A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862647151P 2018-03-23 2018-03-23
PCT/CA2019/050353 WO2019178699A1 (en) 2018-03-23 2019-03-22 Precision glycoconjugates as therapeutic tools

Publications (1)

Publication Number Publication Date
CU20200068A7 true CU20200068A7 (es) 2021-04-07

Family

ID=67984537

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000068A CU20200068A7 (es) 2018-03-23 2019-03-22 Glicoconjugados de precisión como herramientas terapéuticas

Country Status (14)

Country Link
US (2) US10610576B2 (es)
EP (1) EP3768309A4 (es)
JP (1) JP7297047B2 (es)
KR (1) KR20200141053A (es)
CN (1) CN111615400A (es)
AU (1) AU2019239890A1 (es)
BR (1) BR112020018974A2 (es)
CA (1) CA3094406C (es)
CU (1) CU20200068A7 (es)
IL (1) IL277415B (es)
MX (1) MX2020009825A (es)
RU (1) RU2020131305A (es)
SG (1) SG11202009113PA (es)
WO (1) WO2019178699A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021056098A1 (en) * 2019-09-23 2021-04-01 Koranex Capital Neoglycoconjugates as vaccines and therapeutic tools
CN112125832B (zh) * 2020-08-12 2022-09-20 北京大学 刺突蛋白受体结合结构域纳米凝胶及其制备方法与应用
WO2022198314A1 (en) * 2021-03-23 2022-09-29 Koranex Capital Antibodies binding to o-linked carbohydrates on sars-cov-2 spike protein and uses thereof
CN113274488B (zh) * 2021-04-30 2023-08-29 山东省药学科学院 一种特异性预防真菌感染的寡糖疫苗及其制备方法
CN115671274B (zh) * 2022-09-29 2024-03-12 普大生物科技(泰州)有限公司 一种载体蛋白与多糖共价键连接成结合物的方法及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US6248334B1 (en) * 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
HU228700B1 (en) * 1998-07-22 2013-05-28 Stichting Dienst Landbouwkundi Streptococcus suis vaccines and diagnostic tests
CU22904A1 (es) * 1999-08-30 2004-01-23 Univ De Ottawa Oligosacáridos derivados de ribosa- ribitol-fosfato, métodos para prepararlos, inmunógenos que los comprenden y vacunas que comprenden dichos inmunógenos
ES2509894T3 (es) * 2008-05-19 2014-10-20 Idexx Laboratories Inc Métodos, dispositivos, kits y composiciones para detectar gusano redondo, gusano látigo y gusano de gancho
EP2455187A1 (de) * 2010-11-23 2012-05-23 Schneider GmbH & Co. KG Vorrichtung und Verfahren zum Bearbeiten einer optischen Linse
WO2012069188A1 (en) * 2010-11-24 2012-05-31 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V Continuous flow processes for photoconjugation of high-molecular chemical entities
US9517274B2 (en) * 2012-08-16 2016-12-13 Pfizer Inc. Glycoconjugation processes and compositions
PT3363806T (pt) * 2012-12-20 2022-12-16 Pfizer Processo de glicoconjugação
ITMI20130142A1 (it) * 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
WO2015189478A1 (en) * 2014-06-13 2015-12-17 Glykos Finland Oy Payload-polymer-protein conjugates
BR112017006447A2 (pt) * 2014-10-09 2017-12-12 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd processo de conjugação e conjugados sintéticos de oligossacarídeo-proteína obtidos dos mesmos
US10363319B2 (en) * 2014-10-31 2019-07-30 The Board Of Regents Of The Univerity Of Texas System Glycoconjugates and methods for their use
EP3271329B1 (en) * 2015-03-19 2021-08-18 Hangzhou Dac Biotech Co., Ltd Novel hydrophilic linkers and ligand-drug conjugates thereof
US11497701B2 (en) * 2015-09-22 2022-11-15 Chemgreen Innovation Inc. Multi-functional anti-microbial polymers and compositions containing same

Also Published As

Publication number Publication date
RU2020131305A (ru) 2022-04-26
IL277415A (en) 2020-11-30
US10610576B2 (en) 2020-04-07
BR112020018974A2 (pt) 2021-01-05
EP3768309A1 (en) 2021-01-27
US20190290746A1 (en) 2019-09-26
EP3768309A4 (en) 2021-12-01
KR20200141053A (ko) 2020-12-17
US20200261560A1 (en) 2020-08-20
CA3094406C (en) 2024-05-14
CA3094406A1 (en) 2019-09-26
JP2021518435A (ja) 2021-08-02
SG11202009113PA (en) 2020-10-29
WO2019178699A1 (en) 2019-09-26
AU2019239890A1 (en) 2020-10-15
CN111615400A (zh) 2020-09-01
MX2020009825A (es) 2020-12-11
JP7297047B2 (ja) 2023-06-23
IL277415B (en) 2022-04-01

Similar Documents

Publication Publication Date Title
CU20200068A7 (es) Glicoconjugados de precisión como herramientas terapéuticas
CL2019000067A1 (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos.
CL2018003520A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco.
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
BR112019005697A2 (pt) anticorpos anti-muc16-cd3 biespecíficos e conjugados de fármaco e anti-muc16
CY1123534T1 (el) Αντισωματα που περιλαμβανουν τροποποιημενες βαριες σταθερες περιοχες
BR112019011450A2 (pt) células naturais killer modificadas e uso das mesmas
BR112018002844A2 (pt) receptores de antígeno quimérico à base de anticorpos de domínio único e métodos de uso dos mesmos
CY1113760T1 (el) Εμβολιο
EA201991763A1 (ru) Конъюгаты антитела к ccr7 и лекарственного средства
BR112017003194B8 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição
BR112018012352A2 (pt) anticorpos anti-lag3 e fragmentos de ligação ao antígeno
AR112604A1 (es) Receptores de células t, e inmunoterapia usando los mismos
UA114502C2 (uk) Вакцина mycoplasma hyopneumoniae
PH12018502250A1 (en) Cancer immunotherapy by immune activation for immune modulation via globo series antigens
BR9306984A (pt) Análogo de antígeno de peptídeo de um antígeno de peptídeo nativo vacina anticorpo processo para vacinar um hospedeiro necessitando deste tratamento estojo diagnóstico processos para preparar um análogo de um antiígeno de um antígeno de peptídeo nativo para preparar uma vacina para analisar uma amostra para um antígeno de peptídeo nativo e para analisar uma amostra para um anticorpo
BR112017017293A2 (pt) método para predizer modificações de aminoácidos, para selecionar e/ou classificar modificações de aminoácidos e para fornecer uma vacina e vacina
BR112015021921A2 (pt) Anticorpos biespecíficos tetravalente
CL2019000366A1 (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.
BR112014031689A2 (pt) anticorpos reativos cruzados anti-jagged 1/jagged 2, anticorpos anti-jagged ativáveis e métodos de uso deles
CY1123520T1 (el) Μεθοδοι για την προβλεψη της χρησιμοτητας των νεων αντιγονων για ανοσοθεραπεια
ECSP21052193A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
BR112022011032A2 (pt) Conjugado de anticorpo-fármaco anti-claudina e uso farmacêutico do mesmo
BR112022003740A2 (pt) Anticorpos anti-cd96 e métodos de uso dos mesmos
CO2020005347A2 (es) Anticuerpos y conjugados de anticuerpo-fármaco específicos para cd123 y usos de los mismos